Dynavax Technologies Q4 2024 Earnings Report $12.65 -0.20 (-1.56%) As of 04:00 PM Eastern Earnings HistoryForecast Dynavax Technologies EPS ResultsActual EPS$0.05Consensus EPS $0.05Beat/MissMet ExpectationsOne Year Ago EPSN/ADynavax Technologies Revenue ResultsActual Revenue$72.03 millionExpected Revenue$72.70 millionBeat/MissMissed by -$673.00 thousandYoY Revenue GrowthN/ADynavax Technologies Announcement DetailsQuarterQ4 2024Date2/20/2025TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptDVAX Earnings History Remove Ads Dynavax Technologies Earnings HeadlinesDynavax Files Preliminary Proxy StatementApril 3 at 5:40 PM | prnewswire.comWall Street Analysts See an 83.1% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?March 12, 2025 | msn.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 4, 2025 | Porter & Company (Ad)Deep Track Capital sends letter to Dynavax Technologies’ boardMarch 11, 2025 | markets.businessinsider.comDeep Track Capital Sends Letter to Dynavax Technologies’ Board of DirectorsMarch 10, 2025 | finance.yahoo.comDynavax to execute debt refinancingMarch 6, 2025 | seekingalpha.comSee More Dynavax Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dynavax Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dynavax Technologies and other key companies, straight to your email. Email Address About Dynavax TechnologiesDynavax Technologies (NASDAQ:DVAX), a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.View Dynavax Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.